Upcoming regulatory changes to create new opportunity for specialized offerings.
Mark Trusheim
Advertisement
Articles by Mark Trusheim
Pharmaceutical Executive
An overview of Orphan Reinsurer and Benefit Managers groups, including potential challenges with the model and various model suggestions.
Advertisement
Latest Updated Articles
Improving Management of Gene and Cell TherapiesSeptember 10th 2018
Advertisement
Advertisement
Trending on PharmExec
1
What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them
2
TrumpRx Selling Medicines at Higher Prices Than Other Countries: Report
3
What Governance Resets Should Pharma Companies Take in Response to AI?
4
FDA Approves Icotyde as Treatment of Moderate-to-Severe Plaque Psoriasis in Adults and Adolescents
5